AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.2540
-0.0044 (-1.70%)
At close: Aug 24, 2026, 4:00 PM EDT
0.2562
+0.0022 (0.87%)
After-hours: Aug 24, 2026, 7:30 PM EDT
AIM ImmunoTech Revenue
AIM ImmunoTech had revenue of $26.00K in the quarter ending June 30, 2026, with 4.00% growth. This brings the company's revenue in the last twelve months to $95.00K, up 25.00% year-over-year. In the year 2025, AIM ImmunoTech had annual revenue of $88.00K, down -48.24%.
Revenue (ttm)
$95.00K
Revenue Growth
+25.00%
P/S Ratio
82.27
Revenue / Employee
$4,524
Employees
21
Market Cap
7.73M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 88.00K | -82.00K | -48.24% |
| Dec 31, 2024 | 170.00K | -32.00K | -15.84% |
| Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
| Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
| Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
| Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
| Dec 31, 2019 | 140.00K | -227.00K | -61.85% |
| Dec 31, 2018 | 367.00K | -70.00K | -16.02% |
| Dec 31, 2017 | 437.00K | 345.00K | 375.00% |
| Dec 31, 2016 | 92.00K | -41.00K | -30.83% |
| Dec 31, 2015 | 133.00K | -64.00K | -32.49% |
| Dec 31, 2014 | 197.00K | 47.00K | 31.33% |
| Dec 31, 2013 | 150.00K | -63.00K | -29.58% |
| Dec 31, 2012 | 213.00K | 52.00K | 32.30% |
| Dec 31, 2011 | 161.00K | 26.00K | 19.26% |
| Dec 31, 2010 | 135.00K | 24.00K | 21.62% |
| Dec 31, 2009 | 111.00K | -154.00K | -58.11% |
| Dec 31, 2008 | 265.00K | -794.00K | -74.98% |
| Dec 31, 2007 | 1.06M | 126.00K | 13.50% |
| Dec 31, 2006 | 933.00K | -150.00K | -13.85% |
| Dec 31, 2005 | 1.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 4.99M |
| Xenetic Biosciences | 3.26M |
| Traws Pharma | 2.73M |
| Exicure | 500.00K |
| Can-Fite BioPharma | 405.00K |
| Azitra | 7.50K |
| Aprea Therapeutics | 5.19K |
| Ernexa Therapeutics | 1,000.00 |
AIM News
- 12 days ago - AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' Article - GlobeNewsWire
- 17 days ago - AIM ImmunoTech Quarterly report: Q2 2026 - Filings
- 17 days ago - AIM ImmunoTech Earnings release: Q2 2026 - Filings
- 21 days ago - AIM ImmunoTech Ahead of Schedule on ‘Last Dose' DURIPANC Critical Clinical Inflection Point - GlobeNewsWire
- 6 weeks ago - AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Proxy statement: Proxy filing - Filings
- 2 months ago - AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones - GlobeNewsWire
- 2 months ago - AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences - Business Wire